Administration of PDE4 inhibitors suppressed the pannus-like inflammation by inhibition of cytokine production by macrophages and synovial fibroblast proliferation

Mediators of Inflammation

Volumn 2007, Issue , 2007, Pages

  Kobayashi, Katsuya ^a   Suda, Toshio ^a   Manabe, Haruhiko ^a   Miki, Ichiro ^a  

^a KYOWA HAKKO KOGYO CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BOVINE SERUM ALBUMIN; CILOMILAST; DICLOFENAC; HYDROXYPROLINE; INTERLEUKIN 12; INTERLEUKIN 1BETA; KF 66490; LEFLUNOMIDE; LIPOPOLYSACCHARIDE; METHOTREXATE; MYELOPEROXIDASE; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; THIOGLYCOLIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; PHOSPHODIESTERASE IV;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG MECHANISM; ENZYME ACTIVITY; GRANULOMA; INFLAMMATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; ANIMAL; BAGG ALBINO MOUSE; DRUG ANTAGONISM; FIBROBLAST; METABOLISM; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; SYNOVIUM;

ANIMALIA; BOVINAE; MURINAE; MUS; RATTUS;

ADMINISTRATION, ORAL; ANIMALS; ARTHRITIS, RHEUMATOID; CELL PROLIFERATION; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 4; CYTOKINES; FIBROBLASTS; INFLAMMATION; INJECTIONS, SUBCUTANEOUS; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; SERUM ALBUMIN, BOVINE; SYNOVIAL MEMBRANE;

EID: 36248968089     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2007/58901     Document Type: Article

References (39)

1. D. E. Trentham A. S. Townes A. H. Kang Autoimmunity to type II collagen: an experimental model of arthritis. Journal of Experimental Medicine 146 3 1977 857 868
2. K. D. Rainsford Adjuvant polyarthritis in rats: is this a satisfactory model for screening anti-arthritic drugs? Agents & Actions 12 4 1982 452 458
3. K. Magari S. Miyata susumu_miyata@po.fujisawa.co.jp Y. Ohkubo S. Mutoh Inflammatory cytokine levels in paw tissues during development of rat collagen-induced arthritis: effect of FK506, an inhibitor of T cell activation. Inflammation Research 53 9 2004 469 474
4. G. Engelhardt D. Homma K. Schlegel R. Utzmann C. Schnitzler Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflammation Research 44 10 1995 423 433
5. C. Vingsbo P. Sahlstrand J. G. Brun R. Jonsson T. Saxne R. Holmdahl Pristane-induced arthritis in rats: a new model for rheumatoid arthritis with a chronic disease course influenced by both major histocompatibility complex and non-major histocompatibility complex genes. American Journal of Pathology 149 5 1996 1675 1683
6. C. J. Dunn A. J. Gibbons S. K. Miller Development of a delayed-type hypersensitivity granuloma model in the mouse for the study of chronic immune-mediated inflammatory disease. Agents & Actions 27 3-4 1989 365 368
7. C. J. Dunn L. A. Galinet A. J. Gibbons S. K. Shields Murine delayed-type hypersensitivity granuloma: an improved model for the identification and evaluation of different classes of anti-arthritic drugs. International Journal of Immunopharmacology 12 8 1990 899 904
8. B. Särnstrand A.-H. Jansson G. Matuseviciene A. Scheynius S. Pierrou H. Bergstrand hakan.bergstrand@draco.se.astra.com N, N′ -diacetyl-L-cystine - the disulfide dimer of N-acetylcysteine - is a potent modulator of contact sensitivity/delayed type hypersensitivity reactions in rodents. Journal of Pharmacology and Experimental Therapeutics 288 3 1999 1174 1184
9. W. Bäumer wolfgang.baeumer@tiho-hannover.de J. Hoppmann C. Rundfeldt M. Kietzmann Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflammation & Allergy - Drug Targets 6 1 2007 17 26
10. L. Sekut D. Yarnall S. A. Stimpson Anti-inflammatory activity of phosphodiesterase (PDE)-IV inhibitors in acute and chronic models of inflammation. Clinical & Experimental Immunology 100 1 1995 126 132
11. J. N. Francischi C. M. Yokoro S. Poole W. L. Tafuri F. Q. Cunha M. M. Teixeira mmtex@icb.ufmg.br Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. European Journal of Pharmacology 399 2-3 2000 243 249
12. L. Wollin stefan-lutz.wollin@altanapharma.com D. S. Bundschuh A. Wohlsen D. Marx R. Beume Inhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitors. Pulmonary Pharmacology & Therapeutics 19 5 2006 343 352
13. A. Kanehiro T. Ikemura M. J. Mäkelä Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. American Journal of Respiratory and Critical Care Medicine 163 1 2001 173 184
14. F. J. Johnson JohnsonFJ@Cardiff.ac.uk L. J. Reynolds T. J. Toward Elastolytic activity and alveolar epithelial type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and rolipram. Toxicology and Applied Pharmacology 207 3 2005 257 265
15. S. E. Ross R. O. Williams L. J. Mason Suppression of TNF-α expression, inhibition of Th1 activity, and amelioration of collagen-induced arthritis by rolipram. Journal of Immunology 159 12 1997 6253 6259
16. Z. Huang J. A. Mancini josep_mancini@merck.com Phosphodiesterase 4 inhibitors for the treatment of asthma and COPD. Current Medicinal Chemistry 13 27 2006 3253 3562
17. N. Cooper M. M. Teixeira J. Warneck A comparison of the inhibitory activity of PDE4 inhibitors on leukocyte PDE4 activity in vitro and eosinophil trafficking in vivo. British Journal of Pharmacology 126 8 1999 1863 1871
18. P. L. van Lent K. Nabbe A. B. Blom Role of activatory FcγRI and FcγRIII and inhibitory FcγRII in inflammation and cartilage destruction during experimental antigen-induced arthritis. American Journal of Pathology 159 6 2001 2309 2320
19. C. Romay cheyla@quimica.cneuro.edu.cu N. Ledón R. González Further studies on anti-inflammatory activity of phycocyanin in some animal models of inflammation. Inflammation Research 47 8 1998 334 338
20. C. Jakubzick E. S. Choi B. H. Joshi Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. Journal of Immunology 171 5 2003 2684 2693
21. F. A. Meyer I. Yaron V. Mashiah M. Yaron Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts. Journal of Rheumatology 20 2 1993 238 242
22. N. J. Olsen L. M. Murray Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis & Rheumatism 32 4 1989 378 385
23. G. S. Firestein gfirestein@ucsd.edu Evolving concepts of rheumatoid arthritis. Nature 423 6937 2003 356 361
24. A. Bucht P. Larsson L. Weisbrot Expression of interferon-gamma (IFN-γ), IL-10, IL-12 and transforming growth factor-beta (TGF-β) mRNA in synovial fluid cells from patients in the early and late phases of rheumatoid arthritis (RA). Clinical & Experimental Immunology 103 3 1996 357 367
25. Y. Morita M. Yamamura K. Nishida Expression of interleukin-12 in synovial tissue from patients with rheumatoid arthritis. Arthritis & Rheumatism 41 2 1998 306 314
26. F. Puppo puppof@unige.it G. Murdaca M. Ghio F. Indiveri Emerging biologic drugs for the treatment of rheumatoid arthritis. Autoimmunity Reviews 4 8 2005 537 541
27. E. H. Choy ernest.choy@kcl.ac.uk D. A. Isenberg T. Garrood Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. Arthritis & Rheumatism 46 12 2002 3143 3150
28. N. Nishimoto norihiro@fbs.osaka-u.ac.jp K. Yoshizaki N. Miyasaka Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. Arthritis & Rheumatism 50 6 2004 1761 1769
29. V. Kouskoff A.-S. Korganow V. Duchatelle C. Degott C. Benoist D. Mathis Organ-specific disease provoked by systemic autoimmunity. Cell 87 5 1996 811 822
30. M. Feldmann F. M. Brennan R. N. Maini Role of cytokines in rheumatoid arthritis. Annual Review of Immunology 14 1996 397 440
31. D. E. Griswold E. F. Webb A. M. Badger SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor α and interleukin-4 production in vivo. Journal of Pharmacology and Experimental Therapeutics 287 2 1998 705 711
32. H.-S. Cha chahs@samsung.co.kr T. J. Kim J.-Y. Kim Autoantibodies to glucose-6-phosphate isomerase are elevated in the synovial fluid of rheumatoid arthritis patients. Scandinavian Journal of Rheumatology 33 3 2004 179 184
33. M. Schaller W. Stohl V. Benoit S.-M. Tan L. Johansen H. J. Ditzel hditzel@health.sdu.dk Patients with inflammatory arthritic diseases harbor elevated serum and synovial fluid levels of free and immune-complexed glucose-6-phosphate isomerase (G6PI). Biochemical and Biophysical Research Communications 349 2 2006 838 845
34. K. Yamaki X. Li H. Uchida Effects of the phosphodiesterase IV inhibitor rolipram on Th1 and Th2 immune responses in mice. Journal of Pharmacy and Pharmacology 56 7 2004 877 882
35. K. Yamaki X. Li M. A. Hossain Difference in preventive effects between the phosphodiesterase IV inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice. Immunological Investigations 36 2 2007 131 145
36. A. Hatzelmann C. Schudt Anti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitro. Journal of Pharmacology and Experimental Therapeutics 297 1 2001 267 279
37. D. Claveau S. L. Chen S. O'Keefe Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-{2-(3,4- bisdifluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl) -phenyl]-ethyl}-3-methylpyridine-1-oxide], a Potent and Selective Phosphodiesterase 4 Inhibitor. Journal of Pharmacology and Experimental Therapeutics 310 2 2004 752 760
38. H. C. Heystek A.-C. Thierry P. Soulard C. Moulon Corinne. Moulon@dictagene.ch Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity. International Immunology 15 7 2003 827 835
39. I. B. McInnes i.b.mcinnes@clinmed.gla.ac.uk G. Schett Cytokines in the pathogenesis of rheumatoid arthritis. Nature Reviews Immunology 7 6 2007 429 442